Data from a comparative phase II study reveal improvements in progression-free survival among patients with oligometastatic non-small-cell lung cancer (≤5 metastases) receiving consolidative stereotactic ablative radiotherapy (SABR) plus maintenance chemotherapy after induction chemotherapy, relative to those receiving chemotherapy alone (9.7 months versus 3.5 months; P = 0.01). SABR, delivered to all disease sites, had no marked effect on the risk of adverse events, indicating a need for further trials of this approach in larger cohorts.
References
Iyengar, P. et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer. JAMA Oncol. http://dx.doi.org/10.1001/jamaoncol.2017.3501 (2017)
Rights and permissions
About this article
Cite this article
Sidaway, P. SABR effective against oligometastatic disease. Nat Rev Clin Oncol 14, 712 (2017). https://doi.org/10.1038/nrclinonc.2017.165
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.165